Kidney stones have an overall incidence of two to three percent in western countries. In many patients, the disease process is difficult to control and recurrence rates are high: 20 to 50 percent over the subsequent ten years. The pathogenesis and standard methods of treatment for the five major types of stones (i.e., calcium oxalate, struvite, calcium phosphate, uric acid, and cystine) are reviewed. Three new drugs are reviewed in the context of their roles in the selective treatment of kidney stones. Cellulose sodium phosphate (Calcibind) is a nonabsorbable ion-exchange resin with a limited indication for the treatment of calcium stones associated with absorptive hypercalciuria Type I. Acetohydroxamic acid (Lithostat) is an urease-inhibitor that is indicated as adjunctive therapy in patients with chronic urea-splitting urinary tract infections and struvite stones. Potassium citrate (Urocit) is an investigational agent that has clinical efficacy in patients with calcium oxalate and calcium phosphate stones who are hypocitraturic. In addition, potassium citrate is an alkalinizing agent that can be used in patients with uric acid stones.
SierakowskiRFinlaysonBLandesRRFinlaysonCDSierakowskiN. The frequency of urolithiasis in hospital discharge diagnoses in the United States. Invest Urol1978; 15: 438–41.
2.
WilliamsRE. Long-term survey of 538 patients with upper urinary tract stones. Br J Urol1963; 35: 416–37.
3.
BlacklockNJ. The pattern of urolithiasis in the Royal Navy. In: HodgkinsonANordinBEC, eds. Proceedings of the Renal Stone Research Symposium. London: Churchill, 1969: 33.
4.
FinlaysonB. Physiochemical aspects of urolithiasis. Kidney Int1978; 13: 344–60.
5.
FleischH. Inhibitors and promoters of stone formation. Kidney Int1978; 13: 361–71.
6.
BroadusAEThierSO. Metabolic basis of renal-stone disease. N Engl J Med1979; 300: 839–45.
7.
StewartAFBroadusAE. The regulation of renal calcium excretion: An approach to hypercalciuria. Ann Rev Med1981; 32: 457–73.
8.
CoeFL. Prevention of kidney stones. Am J Med1981; 71: 514–6.
9.
PakCYCBrittonFPetersonR. Ambulatory evaluation of nephrolithiasis. Am J Med1980; 69: 19–30.
10.
PakCYCSakhaeeKCrowtherCBrinkleyL. Evidence justifying a high fluid intake in treatment of nephrolithiasis. Ann Intern Med1980; 93: 36–9.
11.
SmithLHVan den BergCJWilsonDM. Current concepts in nutrition: Nutrition and urolithiasis. N Engl J Med1978; 298: 87–9.
12.
MafflyRH. Nephrology. In: RubensteinEFedermanD, eds. Scientific American medicine. VIII. Nephrolithiasis. New York: Scientific American Incorporated, 1982; 10: VIII: 1–7.
ParksJCoeFLFavusM. Hyperparathyroidism in nephrolithiasis. Arch Intern Med1980; 140: 1479–81.
20.
CoeFL. Treated and untreated recurrent calcium nephrolithiasis in patients with idiopathic hypercalciuria, hyperuricosuria or no metabolic disorder. Ann Intern Med1977; 87: 404–10.
CoeFLMoranEKavalichAG. The contribution of dietary purine over-consumption to hyperuricosuria in calcium oxalate stone formers. J Chronic Dis1976; 29: 793–800.
23.
SmithLH. Enteric hyperoxaluria and other hyperoxaluric states. In: CoeFLBrennerBMSteinJH., eds. Contemporary issues in nephrology. 5. Nephrolithiasis. New York: Churchill Livingstone, 1980: 136–64.
24.
WilliamsHESmithLH. Primary hyperoxaluria. In: StanburyJBWyngaardenJBFredericksonDS, eds. The metabolic basis of inherited disease. New York: McGraw-Hill, 1978: 182–204.
25.
PakCYCPetersPKadeskyM. Is selective therapy of recurrent nephrolithiasis possible?Am J Med1981; 71: 615–22.
26.
YendtERCohanimM. Prevention of calcium stones with thiazides. Kidney Int1978; 13: 397–409.
27.
MaschioGTessitoreND'angeloA. Prevention of calcium nephrolithiasis with low-dose thiazide, amiloride, and allopurinol. Am J Med1981; 71: 623–6.
28.
BackmanUDanielsonBGJohannsonGLjunghallSWikstromB. Effects of therapy of bendroflumethiazide in patients with recurrent renal calcium stones. Br J Urol1979; 41: 175–7.
ThomasWC. Use of phosphates in patients with calcareous renal calculi. Kidney Int1978; 13: 390–6.
31.
EttingerB. Recurrent nephrolithiasis: Natural history and effect of phosphate therapy. Am J Med1976; 61: 200–6.
32.
LauKWolfCNussbaumP. Differing effects of acid versus neutral phosphate therapy of hypercalciuria. Kidney Int1979; 16: 736–42.
33.
GriffithDPMusherDM. Pathogenesis of infection stones. In: FinlaysonBThomasWC, eds. Proceedings of the International Colloquium on Urinary Stones. Gainesville: University of Florida, 1976: 54–65.
34.
GriffithDPBruceRRFishbeinWN. Infection (urease)-induced stones. In: CoeFLBrennerBMSteinJH, eds. Contemporary issues in nephrology. 5. Nephrolithiasis. New York: Churchill Livingstone, 1980: 231–60.
35.
GriffithDPGibsonJRClintonCWMusherDM. Acetohydroxamic acid: Clinical studies of a urease inhibitor in patients with staghorn renal calculi. J Urol1978; 119: 9–15.
36.
WojewskiAZajaczkowskiT. The treatment of bilateral staghorn calculi of the kidneys. Int Urol Nephrol1974; 5: 249–60.
37.
SinghMChapmanRTresidderGCBlandyJ. The fate of unoperated staghorn calculous. Br J Urol1973; 45: 581.
ThierSOSegalSFoxMBlairARosenbergLE. Cystinuria: Defective intestinal transport of dibasic amino acids and cystine. J Clin Invest1965; 44: 442–8.
40.
DentCEFriedmanMGreenHWatsonLCA. Treatment of cystinuria. Br Med J1965; 1: 403–7.
41.
PakCYC. Sodium cellulose phosphate: Mechanism of action and effect on mineral metabolism. J Clin Pharmacol1973; 13: 15–27.
42.
PakCYCNicarMNorthcuttC. The definition of the mechanism of hypercalciuria is necessary for the treatment of recurrent stone formers. Contrib Nephrol1982; 33: 136–51.
43.
PietrekJKokotF. Treatment of patients with calcium-containing renal stones with cellulose phosphate. Br J Urol1973; 45: 136–43.
44.
HautmannRHeringFJLutzeyerW. Calcium oxalate stone disease: Effects and side effects of cellulose phosphate and succinate in long-term treatment of absorptive hypercalciuria or hyperoxaluria. J Urol1978; 120: 712–5.
45.
BackmanUDanielsonBGJohanssonGLjunghallSWikstromB. Treatment of recurrent calcium stone formation with cellulose phosphate. J Urol1980; 123: 9–13.
46.
PakCYCDeleaCSBartterFC. Successful treatment of recurrent nephrolithiasis (calcium stones) with cellulose phosphate. N Engl J Med1974; 290: 175–80.
PakCYC. A cautious use of sodium cellulose phosphate in the management of calcium nephrolithiasis. Invest Urol1981; 19: 187–90.
49.
Package insert.Calcibind. Mission Pharmacal Company, San Antonio, Texas, December 1982.
50.
HayashiYKaplanRAPakCYC. Effect of sodium cellulose phosphate therapy in crystallization of calcium oxalate in urine. Metabolism1975; 24: 1273–8.
51.
RobertsonWGPeacockMNordinBEC. Calcium oxalate crystalluria and urine saturation in recurrent renal stone-formers. Clin Sci1971; 40: 365–74.
52.
RobertsonWGPeacockMNordinBEC. Measurement of activity products in urine from stone-formers and normal subjects. In: FinlaysonBHenchLLSmithLH, eds. Urolithiasis: Physical aspects. Washington, DC: National Academy of Sciences, 1972: 79–95.
53.
JohanssonGBackmanUDanielsonBGFellstromBLjunghallSWikstromB. Biochemical and clinical effects of the prophylactic treatment of renal calcium stones with magnesium hydroxide. J Urol1980; 124: 770–4.
54.
GriffithDPMusherDMItinC. Urease: The primary cause of infection-induced urinary stones. Invest Urol1976; 13: 346–50.
55.
MusherDMSaenzCGriffithDP. Interaction between acetohydroxamic acid and twelve antibiotics against fourteen gram-negative pathogens. Antimicrob Agents Chemother1974; 5: 106–10.
56.
MusherDMGriffithDPYawnDRossenRD. Role of urease in pyelonephritis resulting from urinary tract infection with Proteus. J Infect Dis1975; 131: 177–81.
57.
GriffithDPMusherDM. Prevention of infected urinary stones by urease inhibition. Invest Urol1973; 11: 228–33.
58.
FeldmanSPutchaLGriffithDP. Pharmacokinetics of acetohydroxamic acid. Invest Urol1978; 15: 498–501.
59.
WolpertEHofmannAFSummerskillWHJ. Synthesis and metabolism of labeled acetohydroxamic acid, a urease inhibitor. Proc Soc Exp Biol Med1971; 136: 592–6.
60.
MaclArenDM. The influence of acetohydroxamic acid on experimental Proteus pyelonephritis. Invest Urol1974; 12: 146–9.
BurrRGNuseibehI. The effect of oral acetohydroxamic acid on urinary saturation in stone-forming spinal cord patients. Br J Urol1983; 55: 162–5.
64.
RodmanJSWilliamsJJPetersonCM. Partial dissolution of struvite calculus with oral acetohydroxamic acid. Urology1983; 22: 410–2.
65.
Package insert.Lithostat. Mission Pharmacal Company. San Antonio, Texas, June 1983.
66.
PhilipsFSSternbergSSSchwartzHSCroninAPSodergrenJEVidalPM. Hydroxyurea. I. Acute cell death in proliferating tissues in rats. Cancer Res1967; 27: 61–75.
67.
MeyerJLSmithLH. Growth of calcium oxalate crystals. II. Inhibition by natural urinary crystal growth inhibitors. Invest Urol1975; 13: 36–9.
68.
MeyerJLThomasWC. Trace metal-citric acid complexes as inhibitors of calcification and crystal growth. II. Effects of Fe(III), Cr(III), and Al(III) complexes on calcium oxalate crystal growth. J Urol1982; 128: 1376–8.
69.
MeyerJLThomasWCJr. Trace metal-citric acid complexes as inhibitors of calcification and crystal growth. I. Effects of Fe (III), Cr (III), and Al (III) complexes on calcium phosphate crystal growth. J Urol1982; 128: 1372–5.
70.
BisazSFelixRNeumanWFleischH. Quantitative determination of inhibitors of calcium phosphate precipitation in whole urine. Mines Electrolyte Metab1978; 1: 74–83.
71.
UhlirK. The peroral dissolution of renal calculi. J Urol1970; 104: 239–47.
72.
SakhaeeKNicarMHillKPakCYC. Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming salts. Kidney Int1983; 24: 348–52.
73.
SakhaeeKNicarMJacobsenHPakCYC. Potassium alkali therapy of uric acid lithiasis may prevent complication of calcium stones (abstract). Clin Res1982; 30: 403A.
74.
PakCYCSkurlaCBrinkleyLSakhaeeK. Augmentation of renal citrate excretion by oral potassium citrate administration: Time-course, dose frequency schedule, and dose response relationship. J Clin Pharmacol1984; 24: 19–26.
75.
NicarMJPetersonRPakCYC. Utility of potassium citrate as potassium supplement during thiazide therapy of calcium nephrolithiasis. J Urol1984; 131: 430–3.
76.
PakCYCSakhaeeKFullerCJ. Physiological and physiochemical correction and prevention of calcium stone formation by potassium citrate therapy. Trans Assoc Am Physicians1983; 96: 294–305.
77.
NicarMJSkurlaCSakhaeeKPakCYC. Low urinary citrate excretion in nephrolithiasis. Urology1983; 21: 8–14.
